ArticleAntibiotics (Basel, Switzerland)2022
The Antimicrobial Peptide Esc(1-21) Synergizes with Colistin in Inhibiting the Growth and in Killing Multidrug Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- Peptide-based antimicrobial effect against carbapenem-resistantFrontiers in pharmacology · 2026Article
- Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Recent Advances in Antimicrobial Proteins and Peptides: A Promising Clinical Breakthrough and Patent Landscape.Current protein & peptide science · 2026Review
- LTX-315 is a novel broad-spectrum antimicrobial peptide against clinical multidrug-resistant bacteria.Journal of advanced research · 2025Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Advantages and Challenges of Using Antimicrobial Peptides in Synergism with Antibiotics for Treating Multidrug-Resistant Bacteria.ACS infectious diseases · 2025Review
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- The pH-Insensitive Antimicrobial and Antibiofilm Activities of the Frog Skin Derived Peptide Esc(1-21): Promising Features for Novel Anti-Infective Drugs.Antibiotics (Basel, Switzerland) · 2024Article
- An esculentin-1 homolog from a dark-spotted frog (Pelophylax nigromaculatus) possesses antibacterial and immunoregulatory properties.BMC veterinary research · 2024Article
- Medical Device-Associated Healthcare Infections: Sterilization and the Potential of Novel Biological Approaches to Ensure Patient Safety.International journal of molecular sciences · 2023Review
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- The Antimicrobial, Antibiofilm and Anti-Inflammatory Activities of P13#1, a Cathelicidin-like Achiral Peptoid.Pharmaceuticals (Basel, Switzerland) · 2023Article
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- PromisingFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Multidrug-resistant microbial infections and the scarce availability of new antibiotics capable of eradicating them are posing a serious problem to global health security. Among the microorganisms that easily acquire resistance to antibiotics and that are the etiological cause of severe infections, there is
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.